Skip to main content
Fig. 5 | Experimental Hematology & Oncology

Fig. 5

From: IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes

Fig. 5

Mutational spectrum in the younger patients (age < 60 years) and older ones (age ≥ 60 years) with MDS. A The total number of mutations in the younger and older cohorts. B–D Genes related to IPSS-M in younger and older patients, including total number of genes (B), main effect genes (C) and residual genes in IPSS-M (D). E, F Prevalence of main effect genes and residual genes in IPSS-M of different age cohorts. 16 main effect genes in IPSS-M: ASXL1, CBL, DNMT3A, ETV6, EZH2, FLT3, IDH2, KRAS, MLLPTD, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TP53multihit and U2AF1; 15 residual genes in IPSS-M: BCOR, BCORL1, CEBPA, ETNK1, GATA2, GNB1, IDH1, NF1, PHF6, PPM1D, PRPF8, PTPN11, SETBP1, STAG2 and WT1. Abbreviations: IPSS-M: International Prognostic Scoring System-Molecular

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us